Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging

1 Jan 2022

Abstract excerpt

Lipid nanoparticles (LNPs) have been one of the most successful nano-delivery vehicles that enable efficient delivery of cytotoxic chemotherapy agents, antibiotics, and nucleic acid therapeutics. During the coronavirus disease (COVID-19) pandemic, LNP-based COVID-19 messenger RNA (mRNA) vaccines from Pfizer/BioNTech and Moderna have been successfully developed, resulting in global sales of $37 billion and $17.7...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to RNA Interference and Gene Delivery
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36438494
DOI: 10.7150/thno.77259

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imagingPMID 36438494Read ↗

Lipid Nanoparticle Delivery Systems to Enable mRNA-Based TherapeuticsSemantic proximity Read ↗

Lipid nanoparticles in the development of mRNA vaccines for COVID-19Semantic proximity Read ↗

Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugsSemantic proximity Read ↗

Lipid Nanoparticles for In Vivo Lung Delivery of CRISPR-Cas9 Ribonucleoproteins Allow Gene Editing of Clinical TargetsSemantic proximity Read ↗

mRNA Vaccine Platforms and Lipid Nanoparticle Delivery Systems: Molecular Advances, Clinical Breakthroughs, and Regulatory Perspectives (2020–2025)Semantic proximity Read ↗

Revealing a Correlation between Structure and <i>in vitro</i> Activity of mRNA Lipid NanoparticlesSemantic proximity Read ↗

Advances in RNA Therapeutics: Classes, Innovations and Clinical ApplicationsSemantic proximity Read ↗

Enhancing Cytoplasmic Expression of Exogenous mRNA through Dynamic Mechanical StimulationSemantic proximity Read ↗

RNA nanotherapeutics for hepatocellular carcinoma treatmentSemantic proximity Read ↗

Lipid Nanoparticles for Spleen-Targeted RNA deliverySemantic proximity Read ↗

Reengineering mRNA lipid nanoparticles for systemic delivery to pancreasSemantic proximity Read ↗

Impact of Formulation Conditions on Lipid Nanoparticle Characteristics and Functional Delivery of CRISPR RNP for Gene Knock-Out and CorrectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.